Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues

Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues

In the July/August 2006 issue of this journal, the infectious complications associated with the use of infliximab, etanercept and adalimumab were reviewed (1). These represent only three of the many monoclonal antibodies either licensed or in clinical trials for therapeutic use in cancer and autoimm...

Full description

Bibliographic Details
Main Authors: BL Johnston, JM Conly
Format: Article
Language:English
Published: Hindawi Limited 2006-01-01
Series:Canadian Journal of Infectious Diseases and Medical Microbiology
Online Access:http://dx.doi.org/10.1155/2006/876252
id doaj-2976280c5849424aafdc7959537254f2
record_format Article
spelling doaj-2976280c5849424aafdc7959537254f22021-07-02T07:56:41ZengHindawi LimitedCanadian Journal of Infectious Diseases and Medical Microbiology1712-95322006-01-0117632732910.1155/2006/876252Alemtuzumab and Natalizumab: The Monoclonal Antibody Story ContinuesBL Johnston0JM Conly1Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova Scotia, CanadaDepartments of Pathology and Laboratory Medicine, Medicine, and Microbiology and Infectious Diseases, Centre for Antimicrobial Resistance, University of Calgary, Calgary, Alberta, CanadaIn the July/August 2006 issue of this journal, the infectious complications associated with the use of infliximab, etanercept and adalimumab were reviewed (1). These represent only three of the many monoclonal antibodies either licensed or in clinical trials for therapeutic use in cancer and autoimmune disease or to prevent rejection in both solid organ and hematopoietic stem cell transplantation. While most of these agents have not been associated with increased infection rates, alemtuzumab and natalizumab have gained particular attention related to either the frequency or type of infection seen in some individuals who have received them.http://dx.doi.org/10.1155/2006/876252
collection DOAJ
language English
format Article
sources DOAJ
author BL Johnston
JM Conly
spellingShingle BL Johnston
JM Conly
Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
Canadian Journal of Infectious Diseases and Medical Microbiology
author_facet BL Johnston
JM Conly
author_sort BL Johnston
title Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
title_short Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
title_full Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
title_fullStr Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
title_full_unstemmed Alemtuzumab and Natalizumab: The Monoclonal Antibody Story Continues
title_sort alemtuzumab and natalizumab: the monoclonal antibody story continues
publisher Hindawi Limited
series Canadian Journal of Infectious Diseases and Medical Microbiology
issn 1712-9532
publishDate 2006-01-01
description In the July/August 2006 issue of this journal, the infectious complications associated with the use of infliximab, etanercept and adalimumab were reviewed (1). These represent only three of the many monoclonal antibodies either licensed or in clinical trials for therapeutic use in cancer and autoimmune disease or to prevent rejection in both solid organ and hematopoietic stem cell transplantation. While most of these agents have not been associated with increased infection rates, alemtuzumab and natalizumab have gained particular attention related to either the frequency or type of infection seen in some individuals who have received them.
url http://dx.doi.org/10.1155/2006/876252
work_keys_str_mv AT bljohnston alemtuzumabandnatalizumabthemonoclonalantibodystorycontinues
AT jmconly alemtuzumabandnatalizumabthemonoclonalantibodystorycontinues
_version_ 1721335323921743872

Similar Items